tadalafil
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastroparesis
Conditions
Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
Trial Timeline
Apr 1, 2011 → Dec 1, 2013
NCT ID
NCT01326117About tadalafil
tadalafil is a approved stage product being developed by Eli Lilly for Gastroparesis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01326117. Target conditions include Gastroparesis, Diabetic Gastroparesis, Nausea.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02252367 | Approved | Completed |
| NCT02224846 | Approved | Completed |
| NCT01326117 | Approved | Withdrawn |
| NCT01324999 | Phase 2/3 | Completed |
| NCT01183650 | Phase 1 | Completed |
| NCT01066845 | Pre-clinical | Completed |
| NCT00822354 | Pre-clinical | Completed |
| NCT00157326 | Phase 2 | Completed |
| NCT00333281 | Approved | Completed |
| NCT00422578 | Approved | Completed |
| NCT00421083 | Phase 3 | Completed |
| NCT00547417 | Phase 3 | Completed |
| NCT00547599 | Approved | Completed |
Competing Products
19 competing products in Gastroparesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Granisetron | Kyowa Kirin | Phase 2 | 52 |
| Mosapride + domperidone | Sumitomo Pharma | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet | AstraZeneca | Phase 2 | 52 |
| Sitagliptin + Placebo | Merck | Phase 1 | 33 |
| Tegaserod | Novartis | Approved | 85 |
| Reglan ODT | UCB | Pre-clinical | 20 |
| Hemin + Albumin | Recordati | Phase 2 | 49 |
| CNSA-001 + Placebo | PTC Therapeutics | Phase 2 | 49 |
| Immediate-release omeprazole + Delayed-release omeprazole | Bausch Health | Approved | 80 |
| Velusetrag + Placebo | Theravance Biopharma | Phase 2 | 47 |
| velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo | Theravance Biopharma | Phase 2 | 47 |
| IW-9179 + Matching Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| VLY-686 (Tradipitant) | Vanda Pharmaceuticals | Phase 2 | 44 |
| Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |
| Tradipitant | Vanda Pharmaceuticals | Pre-clinical | 15 |
| Tradipitant + Placebo + Open Label Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |